Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Priftin
Rifapentine is a semisynthetic antibiotic belonging to the rifamycin class. It inhibits bacterial RNA polymerase, preventing transcription and thus protein synthesis, making it effective against Mycobacterium tuberculosis. Its long half-life allows for less frequent dosing, improving patient adherence in tuberculosis treatment.
For the treatment of latent and active tuberculosis, often in combination with other antituberculosis drugs.
Outcome:
Decreased rifapentine levels, potential treatment failure
Mechanism:
CYP3A4 induction by rifapentine
Outcome:
Decreased rifapentine absorption
Mechanism:
Chelation/binding
Outcome:
No clinically significant interaction expected
Mechanism:
None known
Most likely new formulation: Long-acting injectable rifapentine (Year: 2026, 70% confidence)
Based on increasing resistance to other tuberculosis drugs, rifapentine use is predicted to increase by 15% in the next 5 years.
Antibiotic, Antitubercular
Rifamycin